INSPECS Group plc (AIM:SPEC)
London · Delayed Price · Currency is GBP · Price in GBX 93.00
-3.00 (-3.13%)
Jul 27, 2026, 2:35 PM GMT
INSPECS Group Revenue
In the year 2025, INSPECS Group had annual revenue of 191.70M GBP, down -0.85%. INSPECS Group had revenue of 94.08M in the half year ending December 31, 2025, with 2.16% growth.
Revenue
191.70M
Revenue Growth
-0.85%
P/S Ratio
0.51
Revenue / Employee
115.76K
Employees
1,656
Market Cap
97.60M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 191.70M | -1.64M | -0.85% |
| Dec 31, 2024 | 193.35M | -9.95M | -4.89% |
| Dec 31, 2023 | 203.29M | 2.34M | 1.16% |
| Dec 31, 2022 | 200.96M | 18.65M | 10.23% |
| Dec 31, 2021 | 182.30M | 147.62M | 425.66% |
| Dec 31, 2020 | 34.68M | -11.51M | -24.91% |
| Dec 31, 2019 | 46.19M | 1.20M | 2.67% |
| Dec 31, 2018 | 44.98M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 45.77B |
| GSK plc | 32.78B |
| Haleon | 11.03B |
| Smith & Nephew | 4.58B |
| EKF Diagnostics Holdings | 51.56M |
| AOTI, Inc. | 49.44M |
| Diaceutics | 38.44M |
| Venture Life Group | 35.17M |
INSPECS Group News
- 2 months ago - INSPECS Group Annual report: H2 2025 - Filings
- 2 months ago - INSPECS Group Annual report: H2 2025 - Filings
- 7 months ago - Inspecs Group Plc Notes H2 Equity Partners' Decision On Not To Make Offer - Nasdaq
- 11 months ago - INSPECS Group Quarterly report: H1 2025 - Filings
- 11 months ago - INSPECS Group Slides: H1 2025 - Filings
- 1 year ago - INSPECS Group Earnings release: H1 2025 - Filings